lapatinib has been researched along with Arrhythmia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, K; Cao, X; Wada, T | 1 |
| Bedja, D; Belmonte, F; Gabrielson, K; Guo, X; Kang, B; Pin, S; Sysa-Shah, P; Tsuchiya, N; Xu, Y | 1 |
2 other study(ies) available for lapatinib and Arrhythmia
| Article | Year |
|---|---|
Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.
Topics: Animals; Antineoplastic Agents; Arrhythmias, Cardiac; Biomarkers; Disease Models, Animal; Dogs; Electrocardiography; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Safety; Troponin I | 2020 |
Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.
Topics: Animals; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Cell Survival; Electrophysiological Phenomena; Gene Expression; Isoproterenol; Lapatinib; Male; Mice; Mice, Transgenic; Myocytes, Cardiac; Organ Size; Organ Specificity; Protein Biosynthesis; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction | 2012 |